Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02483416
- Locations
- 🇫🇷
HOP CHD La Roche sur Yon - Montaigu - Luçon, Pneumo, La Roche Sur Yon cedex, France
🇫🇷CHR d'Annecy, Oncologie, Annecy, Pringy, France
🇫🇷CLI Dr Calabet, Oncolgie, Agen, Agen, France
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 275
- Registration Number
- NCT02453555
- Locations
- 🇯🇵
Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵Nakakinen Clinic, Ibaraki, Naka, Japan
🇯🇵Hiraoka Naika Clinic, Hiroshima, I.M., Hiroshima, Hiroshima, Japan
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT02440854
- Locations
- 🇬🇷
Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece
🇬🇷Chest Hospital of Athens "Sotiria", Athens, Greece
🇬🇷University General Hospital of Heraklion, Heraklion, Greece
Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects
- Conditions
- Healthy
- Interventions
- Drug: BI 1060469, TF1, ReferenceDrug: BI 1060469, TF2, TestDrug: BI 1060469, iFF, Test
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02438696
- Locations
- 🇩🇪
1333.4.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
BI 409306 Cardiac Safety Trial in Healthy Volunteers
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02438683
- Locations
- 🇩🇪
1289.28.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1213
- Registration Number
- NCT02433366
- Locations
- 🇨🇿
Boehringer Ingelheim Investigational Site 113, Sternberk, Czech Republic
🇫🇷Boehringer Ingelheim Investigational Site 29, Besançon, France
🇫🇷Boehringer Ingelheim Investigational Site 35, Eckwersheim, France
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
- Conditions
- Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02417831
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
- Conditions
- Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02417844
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT02417129
- Locations
- 🇨🇿
Boehringer Ingelheim Investigational Site, Praha, Czech Republic
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 730
- Registration Number
- NCT02414958
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States